Table 1.
Baseline characteristics
| Baseline characteristics | Descriptive | |
|---|---|---|
| Age | ||
| Mean ± standard deviation | 60 ± 14 | |
| Median [minimum–maximum] | 63 [18–90] | |
| Years since diagnosis | ||
| Mean ± standard deviation | 7 ± 6 | |
| Median [minimum–maximum] | 5 [0–40] | |
| Sex | Male – N (%) | 192 (47.1%) |
| Female – N (%) | 216 (52.9%) | |
| Familial status | Married / in couple – N (%) | 322 (78.9%) |
| Divorced – N (%) | 36 (8.8%) | |
| Single – N (%) | 32 (7.8%) | |
| Widow – N (%) | 18 (4.4%) | |
| Number of children | ||
| Mean ± standard deviation | 3 ± 1 | |
| Median [minimum–maximum] | 3 [0–7] | |
| I live | With family – N (%) | 356 (87.7%) |
| Alone – N (%) | 48 (11.8%) | |
| Nursing help – N (%) | 2 (0.5%) | |
| Religion | Jewish – N (%) | 396 (98.3%) |
| Arab (Muslim, Christian, Druze) – N (%) | 7 (1.7%) | |
| Country of birth | Israel – N (%) | 289 (71.9%) |
| Europe – N (%) | 42 (10.4%) | |
| Former USSR – N (%) | 27 (6.7%) | |
| America – N (%) | 23 (5.7%) | |
| Africa – N (%) | 12 (3.0%) | |
| Asia & Middle East – N (%) | 9 (2.2%) | |
| Education | Academic – N (%) | 279 (68.9%) |
| Professional – N (%) | 28 (6.9%) | |
| Finished high-school – N (%) | 66 (16.3%) | |
| Did not finish high-school – N (%) | 32 (7.9%) | |
| Occupation | Retiree – N (%) | 140 (34.4%) |
| Work normally or almost normally – N (%) | 121 (29.7%) | |
| Do not work due to hematological condition – N (%) | 69 (17.0%) | |
| Work up to 50%—N (%) | 32 (7.9%) | |
| Do not work due to COVID-19 pandemic – N (%) | 24 (5.9%) | |
| Do not work for other reasons – N (%) | 21 (5.2%) | |
| Hematological disease | Chronic myeloid leukemia – N (%) | 113 (27.8%) |
| Lymphoma – N (%) | 67 (16.5%) | |
| Multiple Myeloma – N (%) | 92 (22.7%) | |
| Myeloproliferative disease – N (%) | 41 (10.1%) | |
| Chronic lymphocytic leukemia – N (%) | 75 (18.5%) | |
| Acute leukemia – N (%) | 14 (3.4%) | |
| Hairy Cell Leukemia – N (%) | 4 (1.0%) | |
| Region of hematological follow-up | Center of Israel – N (%) | 247 (60.7%) |
| Northern Israel – N (%) | 106 (26.0%) | |
| Southern Israel – N (%) | 17 (4.2%) | |
| Jerusalem region – N (%) | 36 (8.8%) | |
| Abroad – N (%) | 1 (0.2%) | |
| Treatment for hematological disease | No treatment – N (%) | 125 (30.6%) |
| Oral – N (%) | 218 (53.4%) | |
| Intravenous and/or subcutaneous – N (%) | 101 (24.7%) | |
Legend: USSR Union of Soviet Socialist Republics